Royalty Pharma plc (RPRX) Operating margin 2018–2025
Royalty Pharma plc (RPRX) operating margin by fiscal year — reported operating income divided by reported revenue.
65.6%FY2025 · since FY2018: 76.0% → 65.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 65.6% | +8.5 pp |
| FY2024 | 57.1% | -6.3 pp |
| FY2023 | 63.4% | +49.6 pp |
| FY2022 | 13.7% | -48.8 pp |
| FY2021 | 62.5% | -12.7 pp |
| FY2020 | 75.2% | -69.4 pp |
| FY2019 | 144.6% | +68.6 pp |
| FY2018 | 76.0% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More RPRX financial trends
RPRX RevenueRPRX Net incomeRPRX Net marginRPRX Gross profitRPRX Gross marginRPRX Operating incomeRPRX Operating cash flowRPRX Free cash flowRPRX Capital expendituresRPRX Return on equityRPRX Stock buybacksRPRX Dividends paidRPRX Total assetsRPRX Total liabilitiesRPRX Shareholders’ equityRPRX overview →